CBDV vs CBD
- CBDV
- In vitro, it inhibits DAGLα and activates and desensitizes TRPV2 Demonstrated (De Petrocellis 2011). Epilepsy and autism have been explored externally and in GWP42006 trials, but human efficacy is not established: our registry has no verified trial result in either direction, catalogue in progress No primary evidence
- CBD
- The most-studied cannabinoid. A purified-CBD prescription medicine is approved for certain rare seizure disorders, a bounded regulatory fact that covers neither consumer products nor CBDV. Most consumer wellness claims are not established; catalogue in progress
From the evidence status row of the table below.
Put a bottle of CBDV beside a bottle of CBD and the two can read like siblings. As molecules, they are: CBDV (cannabidivarin) shares the core structure of CBD (cannabidiol), with a three-carbon side chain where CBD's is longer, which makes it CBD's propyl analog, and neither one is intoxicating. They part company in the research. CBD has been studied extensively in people, while most of CBDV's effects are unestablished, and the wellness benefits marketed for either one are not established. Established
How to read this. Chemical identity, the structural relationship and the lack of intoxication are verified, so they appear as facts with an evidence grade. Claims about effects and benefits, above all anything involving seizures, epilepsy or autism, are reported as other people's claims and never framed as treatment; CBG Atlas does not make, adopt or affirm them. Where verified evidence is missing, you'll see "catalogue in progress." Grades: the six-rung evidence ladder. Not medical, legal, or professional advice.
Side by side
| CBDV | CBD | |
|---|---|---|
| Full name | CBDVCannabidivarin | CBDCannabidiol |
| Formula / CAS | CBDVC₁₉H₂₆O₂ · CAS 24274-48-4 · MW ≈286.41 · dev code GWP42006 | CBDC₂₁H₃₀O₂ · CAS 13956-29-1 · MW ≈314.46 |
| Intoxicating? | CBDVNo Established | CBDNo Established |
| General legal status (2026; not legal advice) | CBDVHemp-derived material falls under the 2018 Farm Bill's ≤0.3% delta-9 THC limit; FDA has not approved it as a food or supplement; novel-food rules apply abroad; state law varies | CBDThe same Farm Bill treatment; FDA has not approved CBD as a food or supplement; state law varies |
| Commonly marketed for (attributed) | CBDVSold as a specialty minor cannabinoid, sometimes with talk of neurological "support" (third-party claims); no approved use | CBDMarketed for stress, relaxation, sleep and general wellness (third-party claims) |
| Evidence status (graded) | CBDVIn vitro, it inhibits DAGLα and activates and desensitizes TRPV2 Demonstrated (De Petrocellis 2011). Epilepsy and autism have been explored externally and in GWP42006 trials, but human efficacy is not established: our registry has no verified trial result in either direction, catalogue in progress No primary evidence | CBDThe most-studied cannabinoid. A purified-CBD prescription medicine is approved for certain rare seizure disorders, a bounded regulatory fact that covers neither consumer products nor CBDV. Most consumer wellness claims are not established; catalogue in progress |
The six rungs, and the words each one permits
- grade: Established
- Settled science — replicated human data, or biochemistry that is not in dispute. “is shown to”
- grade: Demonstrated
- Shown reproducibly in controlled experiments — typically laboratory (in-vitro) work. “has been shown to”
- grade: Emerging
- An early signal — preclinical (animal) work, or human evidence too limited to settle the question. “may · early evidence suggests”
- grade: Low
- Limited and low-confidence — sparse, indirect, or single-source data. “limited evidence · unclear”
- grade: Hypothesized
- Proposed and plausible — but not yet shown. “proposed mechanism”
- grade: Not supported
- Tested, and the evidence does NOT support it. This is a finding against the claim — not an absence of evidence. “evidence does not support”
- Catalogue in progress
- Not a rung: our registry holds nothing graded on the question yet. Absence is not evidence against.
A grade rates the support for a claim across the literature, never a single study. How we grade evidence.
- How to read a cell
- An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
- CB1 cannabinoid receptor
- CBDV: no graded interaction in our registry. CBD: damps activation (negative allosteric modulator; drawn as two bars), in vitro grade: Demonstrated study type: In vitro Laprairie 2015.
- CB2 cannabinoid receptor
- CBDV: no graded interaction in our registry. CBD: blocks what activates it (antagonist of CB1/CB2 agonists), in a review, no rung of its own study type: Review Pertwee 2008.
- α2-adrenoceptor
- CBDV: no graded interaction in our registry. CBD: no graded interaction in our registry.
- 5-HT1A serotonin receptor
- CBDV: no graded interaction in our registry. CBD: activates (agonist; drawn as a chevron), in vitro grade: Demonstrated study type: In vitro Russo 2005.
- TRPV1 and TRPV2 ion channels
- CBDV: no graded interaction in our registry. CBD: no graded interaction in our registry.
- TRPM8 ion channel
- CBDV: no graded interaction in our registry. CBD: no graded interaction in our registry.
What the evidence establishes
Most of what can be said with confidence about the pair is chemistry; CBDV is at an early stage, and most of its effects in people are unestablished. The trouble starts when CBD's much larger record gets borrowed for CBDV, and nowhere more than on seizures and autism, where claims appear below attributed, hedged and marked as not established.
- Structure. CBDV is the propyl homolog of CBD. The two molecules match everywhere but the side chain, three carbons in CBDV and five (pentyl) in CBD, which makes CBDV C₁₉H₂₆O₂ and CBD C₂₁H₃₀O₂. The plant builds them along parallel routes (the acid CBDVA decarboxylates to CBDV, almost completely at around 130 °C/30 min), and neither is made from the other. Established
- Intoxication. Both compounds are non-intoxicating, and the high associated with THC is absent from each. Established
- Verified lab activity for CBDV. In vitro, CBDV inhibits the enzyme DAGLα and activates and desensitizes the TRPV2 ion channel (De Petrocellis 2011): mechanisms seen in the lab, which on their own do not show a benefit in people. Demonstrated
- CBD's mechanisms. Here the gap runs the other way. The wider literature makes CBD the most-studied cannabinoid in humans, yet our registry still lacks a verified CBD receptor anchor, so its mechanisms stay catalogue in progress for now.
- Seizures, epilepsy, autism. Borrowing gets riskiest here. A purified-CBD prescription medicine is approved for certain rare seizure disorders, a bounded regulatory fact that covers neither consumer CBD products nor CBDV. CBDV, under the code GWP42006, has been studied in autism spectrum disorder and explored preclinically for seizures, yet our registry contains no verified CBDV efficacy result in either direction, an empty record rather than a verdict against it No primary evidence · catalogue in progress. Related purified-CBD autism trials, for their part, reported null results, so that CBD claim was tested and failed and is graded Not supported; the finding belongs to CBD and stays with CBD. Neither compound treats any condition. (Not medical advice.)
- Safety & cardiovascular. CBDV's safety file is still open. Trials have looked at tolerability, consumer data are thin (catalogue in progress), and its drug interactions remain uncharacterized. Cardiovascular note: some cannabinoids — notably CBG — act at the α2-adrenoceptor (Cascio 2010), a target linked to blood-pressure regulation; anyone with blood-pressure concerns or on cardiovascular medication should consult a clinician before using any cannabinoid product.
- Drug testing. Standard drug tests look for THC, which leaves CBDV and CBD outside their scope. The risk comes from trace THC in full- or broad-spectrum hemp products, which can produce a positive result. Established (general)
Common questions
What's the difference between CBDV and CBD?
CBDV's side chain is two carbons shorter than CBD's, a three-carbon propyl group in place of a five-carbon pentyl, which makes CBDV (C₁₉H₂₆O₂) the propyl homolog of CBD (C₂₁H₃₀O₂). Both are non-intoxicating. For anyone choosing between them, the gap that counts is in the evidence: CBD has been studied in people far more, and most of CBDV's effects are not established. Established
Does CBDV or CBD help with seizures, epilepsy, or autism?
Neither is established for these uses, and the details matter. A purified-CBD prescription medicine is approved for rare seizure disorders, but that regulatory fact stops at the medicine: it covers neither consumer CBD products nor CBDV. CBDV (GWP42006) has been studied in autism and preclinically for seizures, and our registry holds no verified CBDV efficacy result either way No primary evidence. Related purified-CBD autism trials came back null, so that specific CBD claim is Not supported, and CBD's null result is CBD's alone. Neither is a treatment. (Not medical advice.)
Is CBDV or CBD intoxicating?
Neither one gets you high. THC's high comes through CB1 activation, and CBDV takes after its propyl relative CBD rather than THC, sharing CBD's non-intoxicating profile. Marketing that calls either one "stronger" or "sedating" is describing something controlled human studies have not established. Established
Which is more studied, CBDV or CBD?
CBD, by far: it is the most-studied non-intoxicating cannabinoid, with a large research base and an approved purified-CBD prescription medicine for certain rare seizure disorders (a regulatory fact). CBDV is much earlier in development. It has some external preclinical work and some safety and tolerability trials to its name, and most of its effects remain unestablished. Catalogue in progress. Established
Are CBDV and CBD legal?
Yes, federally in the US as of 2026, for hemp-derived CBDV and CBD under the 2018 Farm Bill, provided the product contains no more than 0.3% delta-9 THC by dry weight. The catch is everything around that line. The FDA has approved neither as a food or supplement, state rules differ, and outside the US novel-food and cannabis regulations apply. Not legal advice. Established
Will CBDV or CBD fail a drug test?
In pure form, neither should: standard tests look for THC rather than these cannabinoids. What trips a test is the trace THC that full- or broad-spectrum hemp products can carry, which can cause a positive. Where testing matters, the certificate of analysis (COA) is the document to read, because it confirms the product's THC content. Established (general)
Sources
- De Petrocellis 2011 — PMID 21175579 — in vitro, CBDV inhibits DAGLα and activates and desensitizes TRPV2. Grade: Demonstrated.
- Cascio 2010 — PMID 20002104 — CBG acts at the α2-adrenoceptor (and 5-HT1A); cited here only to anchor the cardiovascular/blood-pressure caution. Grade: Demonstrated.
- Chemical identity (Established). CBDV: C₁₉H₂₆O₂ · MW ≈286.41 · CAS 24274-48-4 · propyl (varin) homolog of CBD · non-intoxicating · first isolated 1969 · dev code GWP42006 · acid CBDVA (C₂₀H₂₆O₄ · CAS 31932-13-5) decarboxylates near-completely around 130 °C/30 min. CBD: C₂₁H₃₀O₂ · MW ≈314.46 · CAS 13956-29-1 · non-intoxicating.
- Epilepsy / seizures / autism: external preclinical work exists, as do CBDV (GWP42006) trials in autism spectrum disorder, but human efficacy is not established, and related purified-CBD autism trials were null. This is reported as third-party research interest and is never a treatment claim. The approved purified-CBD seizure medicine is a bounded regulatory fact that extends neither to CBDV nor to consumer CBD products.
- Consumer wellness benefits: not established in controlled human studies; reported as third-party claims (catalogue in progress). The page shows no binding or potency figures and gives no dosing.
Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event: if you experienced a possible adverse effect from a cannabinoid product, please report it via the platform's "Report a safety event" path.
Verified anchors: De Petrocellis 2011 (PMID 21175579) · Cascio 2010 (PMID 20002104).
Before you act on what you have read
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event →Keep exploring
The compounds compared
More comparisons